Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Operating Expenses (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Operating Expenses for 14 consecutive years, with $51.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 16.01% year-over-year to $51.9 million, compared with a TTM value of $236.8 million through Dec 2025, down 10.54%, and an annual FY2025 reading of $236.8 million, down 10.54% over the prior year.
  • Operating Expenses was $51.9 million for Q4 2025 at Karyopharm Therapeutics, down from $59.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $82.6 million in Q2 2022 and bottomed at $589000.0 in Q3 2021.
  • Average Operating Expenses over 5 years is $57.9 million, with a median of $66.9 million recorded in 2022.
  • The sharpest move saw Operating Expenses crashed 99.14% in 2021, then surged 11272.5% in 2022.
  • Year by year, Operating Expenses stood at $79.3 million in 2021, then fell by 14.95% to $67.4 million in 2022, then rose by 6.09% to $71.6 million in 2023, then dropped by 13.6% to $61.8 million in 2024, then fell by 16.01% to $51.9 million in 2025.
  • Business Quant data shows Operating Expenses for KPTI at $51.9 million in Q4 2025, $59.3 million in Q3 2025, and $62.3 million in Q2 2025.